FOSAMAX Drug Patent Profile

When do Fosamax patents expire, and what generic alternatives are available?

Fosamax is a drug marketed by Merck, Organon, and Organon Llc. and is included in three NDAs.

The generic ingredient in FOSAMAX is alendronate sodium; cholecalciferol. There are twenty-five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the alendronate sodium; cholecalciferol profile page.

Summary for FOSAMAX

US Patents:	0
Applicants:	3
NDAs:	3
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	171
Clinical Trials:	64
Drug Prices:	Drug price information for FOSAMAX
Drug Sales Revenues:	Drug sales revenues for FOSAMAX
What excipients (inactive ingredients) are in FOSAMAX?	FOSAMAX excipients list
DailyMed Link:	FOSAMAX at DailyMed

See drug prices for FOSAMAX

See drug sales revenues for FOSAMAX

Recent Clinical Trials for FOSAMAX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Taiwan University Hospital	PHASE4
National Taiwan University Hospital, Yun-Lin Branch	PHASE4
Doris Duke Charitable Foundation	Phase 2

See all FOSAMAX clinical trials

Pharmacology for FOSAMAX

Drug Class

Bisphosphonate

Paragraph IV (Patent) Challenges for FOSAMAX

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FOSAMAX	Oral Solution	alendronate sodium	70 mg/75 mL	021575	1	2007-09-07

US Patents and Regulatory Information for FOSAMAX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck	FOSAMAX	alendronate sodium	SOLUTION;ORAL	021575-001	Sep 17, 2003		DISCN	Yes	No
Organon Llc	FOSAMAX PLUS D	alendronate sodium; cholecalciferol	TABLET;ORAL	021762-001	Apr 7, 2005		RX	Yes	No
Organon	FOSAMAX	alendronate sodium	TABLET;ORAL	020560-004	Oct 20, 2000		DISCN	Yes	No
Organon Llc	FOSAMAX PLUS D	alendronate sodium; cholecalciferol	TABLET;ORAL	021762-002	Apr 26, 2007		RX	Yes	Yes
Organon	FOSAMAX	alendronate sodium	TABLET;ORAL	020560-003	Apr 25, 1997		DISCN	Yes	No
Organon	FOSAMAX	alendronate sodium	TABLET;ORAL	020560-001	Sep 29, 1995		DISCN	Yes	No
Organon	FOSAMAX	alendronate sodium	TABLET;ORAL	020560-005	Oct 20, 2000	AB	RX	Yes	Yes

Expired US Patents for FOSAMAX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Organon	FOSAMAX	alendronate sodium	TABLET;ORAL	020560-001	Sep 29, 1995	6,015,801
Organon	FOSAMAX	alendronate sodium	TABLET;ORAL	020560-003	Apr 25, 1997	5,804,570
Organon	FOSAMAX	alendronate sodium	TABLET;ORAL	020560-004	Oct 20, 2000	5,804,570
Organon	FOSAMAX	alendronate sodium	TABLET;ORAL	020560-002	Sep 29, 1995	6,015,801
Organon	FOSAMAX	alendronate sodium	TABLET;ORAL	020560-003	Apr 25, 1997	6,015,801
Organon	FOSAMAX	alendronate sodium	TABLET;ORAL	020560-002	Sep 29, 1995	5,804,570
Organon	FOSAMAX	alendronate sodium	TABLET;ORAL	020560-004	Oct 20, 2000	5,944,329

International Patents for FOSAMAX

See the table below for patents covering FOSAMAX around the world.

Country	Patent Number	Title	Estimated Expiration
Belgium	896453
Switzerland	661437	BIFOSFONATI FARMACOLOGICAMENTE ATTIVI, PROCEDIMENTO PER LA LORO PREPARAZIONE E RELATIVE COMPOSIZIONI FARMACEUTICHE.
Germany	19675047
Germany	3313049
France	2525223	NOUVEAUX ACIDES DIPHOSPHONIQUES, LEURS SELS, LEUR PROCEDE DE PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
United Kingdom	2118042	PHARMACEUTICAL COMPOSITIONS CONTAINING BIPHOSPHONIC ACIDS
United Kingdom	8308791

Supplementary Protection Certificates for FOSAMAX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0998292	CA 2006 00005	Denmark		PRODUCT NAME: ALENDRONSYRE, NATRIUMTRIHYDRAT, COLECALCIFEROL
0998292	PA2006002	Lithuania		PRODUCT NAME: NATRIUM ALENDRONICUM/COLECACIFEROLUM; REGISTRATION NO/DATE: EU/1/05/310/001, EU/1/05/310/002, EU/1/05/310/003, EU/1/05/310/004, EU/1/05/310/005 20050824
0998292	91222	Luxembourg		91222, EXPIRES: 20200824
0998292	PA2006002,C0998292	Lithuania		PRODUCT NAME: NATRIUM ALENDRONICUM/COLECACIFEROLUM; REGISTRATION NO/DATE: EU/1/05/310/001, EU/1/05/310/002, EU/1/05/310/003, EU/1/05/310/004, EU/1/05/310/005 20050824
1175904	PA2007007	Lithuania		PRODUCT NAME: ACIDUM ALENDRONICUM NATRIUM, COLECALCIFEROLUM; REGISTRATION NO/DATE: EU/1/05/310/001 2005 08 24 EU/1/05/310/002 2005 08 24 EU/1/05/310/003 2005 08 24 EU/1/05/310/004 2005 08 24 EU/1/05/310/00 20050824
1175904	CA 2007 00045	Denmark		PRODUCT NAME: ALENDRONSYRE, NATRIUMTRIHYDRAT, OG COLECALCIFEROL
1175904	91364	Luxembourg		91364, EXPIRES: 20200826

FOSAMAX (alendronate) Market Dynamics and Financial Trajectory: Revenue Drivers, Exclusivity and Generic Erosion, and Competitive Positioning

Last updated: July 3, 2026

FOSAMAX (alendronate sodium) is a long-since genericized oral bisphosphonate in osteoporosis. Market growth is constrained by class maturity and dosing frequency, while revenue is driven mainly by switching between branded and generic, channel inventory cycles, and price compression. Post-LOE, the financial trajectory is dominated by generic penetration and payer-centric formulary placement rather than new clinical differentiation.

---

What is FOSAMAX (alendronate) used for, and how do those indications shape demand?

FOSAMAX is a bisphosphonate indicated for osteoporosis in postmenopausal women and in men, and for glucocorticoid-induced osteoporosis in select populations. Demand is therefore tied to:

• Osteoporosis screening and treatment rates
• Adherence to chronic therapy
• Payer coverage of oral bisphosphonates versus alternative anti-resorptives
• Safety and tolerability versus competing agents (notably GI tolerability and persistence)

How does dosing frequency affect retention and market share?

Oral bisphosphonates compete on regimen burden. FOSAMAX is taken once weekly (typical market positioning versus daily regimens). Weekly dosing can improve adherence relative to daily therapy, but it does not overcome class-wide persistence challenges driven by GI side effects and administration requirements.

What are the main competitive substitution pathways inside osteoporosis?

Within osteoporosis, payers often steer to oral generic bisphosphonates, then diversify to branded agents depending on risk profile and history:

• Oral generic bisphosphonates (alendronate, risedronate, ibandronate)
• Prolia (denosumab) and Evenity (romosozumab) for higher-risk patients
• Reclast (zoledronic acid) where infusions are favored
• Tymlos/Forteo (teriparatide) and related anabolic pathways in select settings

---

When did FOSAMAX face generic competition, and what does that imply for revenue?

FOSAMAX has been widely available as generic alendronate for many years. The post-branded period is characterized by:

• Rapid price erosion after first generic approvals
• Persistent channel commoditization driven by multiple ANDA filers
• Ongoing cannibalization as wholesalers rotate supply toward lowest net-cost SKUs

Featured snippet answer: how should FOSAMAX revenue be modeled post-LOE?

Revenue typically declines sharply at initial generic entry and then follows a slower curve shaped by price per unit, volume stability/decline, and market mix shift toward higher-value branded osteoporosis agents.

What generic entry risks apply to FOSAMAX-like bisphosphonate products?

For mature, off-patent small molecules:

• Multiple ANDAs can launch without needing biologic-style manufacturing complexity
• Payer substitution is fast because safety profiles are well understood
• Inventory swings can produce short-term volatility but not sustained brand recovery

---

What market dynamics most impact FOSAMAX performance: pricing, formulary placement, and persistence?

Pricing dynamics

After LOE, branded pricing loses to:

• Net-to-wholesaler price competition
• PBM-driven rebate structures favoring the lowest-cost or preferred generic

In mature osteoporosis, gross-to-net compression can still occur for remaining branded SKUs, but net revenue tends to be structurally pressured.

Formulary dynamics

Formulary placement for oral bisphosphonates is often:

• Favorable for generics in standard-risk members
• Conditional for higher-risk patients where insurers prefer injectable high-potency regimens

Persistence and adherence

The primary utilization limiter inside oral bisphosphonates is adherence. Real-world persistence varies by:

• GI side-effect burden
• Proper administration behavior (upright posture, fasting, water)
• Treatment switching after intolerance

For financial trajectory, this matters because even with generic pricing advantages, therapy discontinuation reduces treated prevalence.

---

Which competitors most pressure FOSAMAX, and how do they compare commercially?

FOSAMAX competes within osteoporosis with both bisphosphonates and non-bisphosphonate anti-resorptives.

Key competitive set

• Other oral bisphosphonates: generic risedronate, ibandronate, and branded/special formulations in limited cases
• Denosumab (Prolia): strong efficacy and convenience (every 6 months), but higher cost and payer restrictions
• Romosozumab (Evenity): time-limited course, market access driven by risk criteria
• Zoledronic acid (Reclast): annual infusion benefits for persistence, but logistics and coverage matter

Commercial comparison (directional)

• FOSAMAX’s economics are built on low cost and wide access.
• Injectables often capture higher-acuity members, but at materially higher net prices.
• Net effect: a channel and payer mix shift can reduce oral bisphosphonate volumes even while oral class volumes remain substantial.

---

What is the financial trajectory pattern for FOSAMAX after patent and exclusivity expiration?

Expected trajectory shape

For mature small molecules:

1. Branded plateau before LOE
2. Step-down at first meaningful generic entries
3. Sustained decline driven by price compression and mix shift
4. Residual brand tail if branded still has formulary access or supply differentiation in limited geographies/packaging

What drives residual branded tail

• Specific dose forms or packaging preferences
• Institutional contracting
• Lag in formulary changes for certain plan designs
• Brand awareness in specific prescriber cohorts

Why the tail does not usually stabilize

Osteoporosis is chronic and competitive; once multiple low-cost generics exist, branded pricing power is constrained.

---

How do rebates, wholesalers, and channel inventory cycles affect FOSAMAX sales?

PBM and rebate mechanics

Generic competition changes the rebate surface:

• PBMs often prefer lowest net cost products, compressing revenue for non-preferred SKUs.
• Branded remaining products may rely on strategic contracting, but the economic center of gravity stays with generics.

Wholesaler stocking

Mature products experience:

• Order timing shifts around supply promotions
• Short-term shipment spikes or pauses tied to channel inventory management

This introduces quarter-to-quarter variability even when long-term treated prevalence is stable.

---

What are the main geographic and access dynamics for FOSAMAX?

FOSAMAX is established across major markets, but market structure differs by:

• Generic availability and number of ANDA/similar products
• Payer formularies and reference pricing
• Local guideline alignment on first-line therapy

In high-generic-competition jurisdictions, brand exposure diminishes quickly. In markets with more limited generic launches, some brand share can persist longer, but with typical long-run convergence toward generic-led pricing.

---

What regulatory and labeling factors matter for ongoing FOSAMAX market uptake?

For oral bisphosphonates, uptake is constrained by:

• Label instructions about administration and contraindications
• Safety monitoring norms
• Education requirements for prescribers and patients

These do not typically prevent generic substitution, but they influence:

• Initiation rate
• Continuation rate
• Switching behavior across osteoporosis regimens

---

What patent and exclusivity status affects the commercial future of FOSAMAX?

FOSAMAX is a mature product with broad generic availability, so the near-term commercial trajectory is not driven by incremental exclusivity. For current market dynamics, the controlling factors are:

• Number of generic entrants
• Litigation and settlement structures that influence launch timing (where applicable historically)
• Ongoing regulatory approvals for additional generic SKUs

Featured snippet answer

The commercial future of FOSAMAX is largely determined by generic market structure and payer preference, not by remaining brand exclusivity.

---

How does FOSAMAX compare to newer osteoporosis biologics and sequencing strategies?

Sequencing in real-world practice

Many payers encourage:

• Oral bisphosphonates first-line for broad populations
• Escalation to injectables for inadequate response, intolerance, or higher-risk fractures

This is financially relevant because it creates a funnel:

• Oral therapy gets volume from baseline patients
• Injectables siphon off riskier or less adherent patients, increasing total treatment spend even if oral volumes remain

Commercial implication

Even if FOSAMAX retains baseline utilization, total osteoporosis spend tends to shift to higher-cost alternatives over time, reducing the relative revenue contribution of oral brands.

---

How many generic competitors typically exist for FOSAMAX, and what does that do to pricing?

For established off-patent small molecules, generic competition usually becomes:

• Multi-filer, multi-NDC
• Highly substitutable at the pharmacy level
• Competitive on net price and dispensing incentives

The financial impact is:

• Rapid normalization of pricing near generics’ lowest-cost equilibrium
• Limited room for premium branded pricing
• Distribution-driven differentiation rather than clinical differentiation

---

What does the FOSAMAX financial trajectory mean for investors and licensing decisions?

Investment framing

For mature genericized brands, valuation models focus on:

• Residual brand share and net realized price
• Prescription volumes net of persistence changes
• Competitive shelf availability and switching sensitivity
• Exposure to channel inventory and PBM contracting renegotiations

Licensing framing

Licensing revenue tied to FOSAMAX is typically constrained unless:

• There are differentiated formulations with improved administration/tolerability
• There is a localized market structure with limited generics
• There are unique supply-chain or packaging protections

Absent differentiation, licensing opportunities are usually limited to legacy arrangements or niche geographies.

---

Key Takeaways

• FOSAMAX demand is anchored in osteoporosis treatment rates, but its revenue trajectory is structurally constrained by generic alendronate penetration and payer-led price compression.
• Market performance is governed more by formulary access, rebate dynamics, persistence, and channel inventory than by clinical differentiation.
• Competitive pressure comes from both oral bisphosphonate generics and injectable high-cost osteoporosis agents that increasingly capture higher-risk patients.
• The long-run financial path for FOSAMAX is a branded residual tail rather than sustained growth, driven by residual share and negotiated net pricing.

---

FAQs

1. Why do oral bisphosphonates like FOSAMAX lose share over time even if they remain first-line?
   Persistence challenges and switching to injectables for higher-risk or intolerant patients.

2. What drives quarter-to-quarter volatility in mature osteoporosis generics?
   Wholesaler inventory management, PBM contracting timing, and NDC-level supply shifts.

3. Can branded FOSAMAX regain pricing power after generic entry?
   Only marginally, typically through short-lived contracting, limited supply conditions, or differentiated packaging, since therapy is highly substitutable.

4. How do osteoporosis treatment guidelines translate into market volume for FOSAMAX?
   Guidelines influence initiation and escalation rates, affecting treated prevalence and patient flow toward oral versus injectable regimens.

5. What market signals would indicate a further decline in FOSAMAX net revenue?
   Additional generic entrants, deeper PBM preference moves to lower-cost SKUs, and increased injectable capture of high-risk fracture populations.

---

References

1. FDA. “Fosamax (alendronate sodium) prescribing information.” U.S. Food and Drug Administration.
2. IMS Institute for Healthcare Informatics (or IQVIA Institute). Market research reports on osteoporosis drug spend trends and class switching dynamics.
3. EMA. European public assessment and product information for alendronate-containing medicines (dose and safety labeling context).

DrugChatter Q&A for FOSAMAX

How long does fosamax stay in your system?
Is fosamax still on the market?
What is the generic for fosamax?
How much does fosamax cost per month?
What is the average cost of fosamax?